Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

APPROVED_FOR_MARKETING

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).

Key facts

Study ID

NCT02171156

Run by

Boehringer Ingelheim

Last updated by the study team

2017-05-08

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed Informed Consent consistent with ICH-GCP and local laws signed prior to entry into the trial;
• Male or female patients aged >=40 years at Visit 1;
• IPF diagnosis based upon the American Thoracic Society (ATS)/European Respiratory Society (ERS) /Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) IPF 2011 guideline within 5 years of visit 1;
• Carbon monoxide diffusing capacity (DLCO)(corrected for Haemoglobin (Hb)): 30%-79% predicted of normal, per institutional standards at the clinic site, at Visit 1;
• Forced Vital Capacity (FVC) >= 50% predicted of normal, per institutional standards at the clinic site, at Visit 1.

You may not qualify if…

• Eligible to participate or participating in an ongoing actively accruing clinical trial with nintedanib in the treatment of IPF.
• Laboratory parameters from Visit 1 must satisfy entry criteria as shown below. Abnormal laboratory parameters may be re-tested if a measurement error is suspected (e.g., there was no abnormal result of this test in the recent history of the patient and there is no related clinical sign). The results of the re-test should be reported within the Screening period (i.e., 28 days of signing the informed consent form).
• ALT, AST > 1.5 times upper limit of normal (ULN);
• Total Bilirubin > 1.5 times upper limit of normal (ULN);
• Bleeding risk:
• patients who require: fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin, etc.), or high-dose antiplatelet therapy. Exceptions: prophylactic low dose heparin or heparin flush as needed for maintenance of an indwelling intravenous device (e.g., enoxaparin 4000 IU s.c. per day) and prophylactic use of antiplatelet therapy (e.g., acetylsalicylic acid up to 325 mg/d, or clopidogrel at 75 mg/d, or equivalent doses of other antiplatelet therapy);
• history of hemorrhagic central nervous system (CNS) event within 12 months of Visit 1;
• any of the following within 3 months of Visit 1;
• hemoptysis or haematuria
• active gastro-intestinal bleeding or ulcers
• major injury or surgery
• coagulation parameters:
• international normalised ratio (INR) > 2
• prothrombin time (PT) and partial thromboplastin time (PTT) > 150% of institutional upper limit of normal (ULN)
• Planned major surgery within the next 3 months, including lung transplantation, major abdominal or major intestinal surgery;
• Thrombotic risk:
• known inherited predisposition to thrombosis
• history of thrombotic event (including stroke and transient ischemic attacks) within 12 months of Visit 1;
• Cardiac disease:
• Myocardial infarction within 6 months of Visit 1
• Unstable angina within 1 month of Visit 1;
• Current or planned usage (during the course of this trial) of any other investigational drug during the course of this trial;
• Current or planned treatment (during the course of this trial) with: pirfenidone, azathioprine, cyclophosphamide, cyclosporine, prednisone >15 mg daily or > 30 mg every 2 days OR equivalent dose of other oral corticosteroids, as well as those listed in exclusion criteria #4 (bleeding risk);
• Permanent discontinuation of nintedanib within a clinical trial, due to adverse events considered drug-related;
• Known hypersensitivity to nintedanib or its excipients;

Where it is running

• 1199.177.1003 Boehringer Ingelheim Investigational Site — Winter Park, Florida, United States
• 1199.177.1012 Boehringer Ingelheim Investigational Site — Skokie, Illinois, United States
• 1199.177.1014 Boehringer Ingelheim Investigational Site — Muncie, Indiana, United States
• 1199.177.1002 Boehringer Ingelheim Investigational Site — Minneapolis, Minnesota, United States
• 1199.177.1011 Boehringer Ingelheim Investigational Site — Charleston, South Carolina, United States
• 1199.177.1022 Boehringer Ingelheim Investigational Site — Spartanburg, South Carolina, United States
• 1199.177.1067 Boehringer Ingelheim Investigational Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.